183 related articles for article (PubMed ID: 22359620)
1. Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma.
McIntyre JB; Bose P; Klimowicz AC; Brockton NT; Petrillo S; Matthews W; Easaw J; Magliocco A; Dort JC
PLoS One; 2012; 7(2):e31723. PubMed ID: 22359620
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
[TBL] [Abstract][Full Text] [Related]
3. Head and neck squamous cell carcinomas do not express EGFRvIII.
Melchers LJ; Clausen MJ; Mastik MF; Slagter-Menkema L; Langendijk JA; van der Laan BF; van der Wal JE; van der Vegt B; Roodenburg JL; Schuuring E
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):454-62. PubMed ID: 25304797
[TBL] [Abstract][Full Text] [Related]
4. Challenges in EGFRvIII detection in head and neck squamous cell carcinoma.
Wheeler SE; Egloff AM; Wang L; James CD; Hammerman PS; Grandis JR
PLoS One; 2015; 10(2):e0117781. PubMed ID: 25658924
[TBL] [Abstract][Full Text] [Related]
5. Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.
Khattri A; Zuo Z; Brägelmann J; Keck MK; El Dinali M; Brown CD; Stricker T; Munagala A; Cohen EE; Lingen MW; White KP; Vokes EE; Seiwert TY
Oral Oncol; 2015 Jan; 51(1):53-8. PubMed ID: 25255959
[TBL] [Abstract][Full Text] [Related]
6. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.
Yoshimoto K; Dang J; Zhu S; Nathanson D; Huang T; Dumont R; Seligson DB; Yong WH; Xiong Z; Rao N; Winther H; Chakravarti A; Bigner DD; Mellinghoff IK; Horvath S; Cavenee WK; Cloughesy TF; Mischel PS
Clin Cancer Res; 2008 Jan; 14(2):488-93. PubMed ID: 18223223
[TBL] [Abstract][Full Text] [Related]
7. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
8. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
9. Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma.
Wheeler S; Siwak DR; Chai R; LaValle C; Seethala RR; Wang L; Cieply K; Sherer C; Joy C; Mills GB; Argiris A; Siegfried JM; Grandis JR; Egloff AM
Clin Cancer Res; 2012 Apr; 18(8):2278-89. PubMed ID: 22351687
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance.
Aldape KD; Ballman K; Furth A; Buckner JC; Giannini C; Burger PC; Scheithauer BW; Jenkins RB; James CD
J Neuropathol Exp Neurol; 2004 Jul; 63(7):700-7. PubMed ID: 15290895
[TBL] [Abstract][Full Text] [Related]
11. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Chau NG; Perez-Ordonez B; Zhang K; Pham NA; Ho J; Zhang T; Ludkovski O; Wang L; Chen EX; Tsao MS; Kamel-Reid S; Siu LL
Head Neck Oncol; 2011 Feb; 3():11. PubMed ID: 21352589
[TBL] [Abstract][Full Text] [Related]
12. Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma.
Tykocinski ES; Grant RA; Kapoor GS; Krejza J; Bohman LE; Gocke TA; Chawla S; Halpern CH; Lopinto J; Melhem ER; O'Rourke DM
Neuro Oncol; 2012 May; 14(5):613-23. PubMed ID: 22492960
[TBL] [Abstract][Full Text] [Related]
13. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.
Blehm KN; Spiess PE; Bondaruk JE; Dujka ME; Villares GJ; Zhao YJ; Bogler O; Aldape KD; Grossman HB; Adam L; McConkey DJ; Czerniak BA; Dinney CP; Bar-Eli M
Clin Cancer Res; 2006 Aug; 12(15):4671-7. PubMed ID: 16899617
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.
Fontanilles M; Marguet F; Ruminy P; Basset C; Noel A; Beaussire L; Viennot M; Viailly PJ; Cassinari K; Chambon P; Richard D; Alexandru C; Tennevet I; Langlois O; Di Fiore F; Laquerrière A; Clatot F; Sarafan-Vasseur N
Acta Neuropathol Commun; 2020 Apr; 8(1):52. PubMed ID: 32303258
[TBL] [Abstract][Full Text] [Related]
15. Expression of Epidermal Growth Factor Receptor variant III in laryngeal carcinoma tissues.
Yang B; Chen J; Zhang X; Cao J
Auris Nasus Larynx; 2009 Dec; 36(6):682-7. PubMed ID: 19427146
[TBL] [Abstract][Full Text] [Related]
16. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.
Modjtahedi H; Khelwatty SA; Kirk RS; Seddon AM; Essapen S; Del Vecchio CA; Wong AJ; Eccles S
Br J Cancer; 2012 Feb; 106(5):883-8. PubMed ID: 22315050
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
[TBL] [Abstract][Full Text] [Related]
19. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation.
Wheeler SE; Suzuki S; Thomas SM; Sen M; Leeman-Neill RJ; Chiosea SI; Kuan CT; Bigner DD; Gooding WE; Lai SY; Grandis JR
Oncogene; 2010 Sep; 29(37):5135-45. PubMed ID: 20622897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
